TipRanks
Advertisement
Advertisement
MapLight Therapeutics reports Q2 EPS ($1.32), consensus ($1.31)
PremiumThe FlyMapLight Therapeutics reports Q2 EPS ($1.32), consensus ($1.31)
2M ago
MapLight Therapeutics price target lowered to $31 from $35 at Raymond James
Premium
The Fly
MapLight Therapeutics price target lowered to $31 from $35 at Raymond James
2M ago
MapLight Therapeutics price target lowered to $21 from $24 at Canaccord
Premium
The Fly
MapLight Therapeutics price target lowered to $21 from $24 at Canaccord
2M ago
MapLight Therapeutics price target lowered to $24 from $43 at Canaccord
PremiumThe FlyMapLight Therapeutics price target lowered to $24 from $43 at Canaccord
3M ago
MapLight downgraded to Equal Weight from Overweight at Morgan Stanley
Premium
The Fly
MapLight downgraded to Equal Weight from Overweight at Morgan Stanley
3M ago
MapLight Therapeutics price target lowered to $26 from $45 at H.C. Wainwright
Premium
The Fly
MapLight Therapeutics price target lowered to $26 from $45 at H.C. Wainwright
3M ago
MapLight Reports Positive Phase 2 Schizophrenia Trial Results
PremiumCompany AnnouncementsMapLight Reports Positive Phase 2 Schizophrenia Trial Results
3M ago
MapLight Therapeutics announces topline results from ZEPHYR trial
Premium
The Fly
MapLight Therapeutics announces topline results from ZEPHYR trial
3M ago
MapLight Therapeutics price target raised to $43 from $35 at Canaccord
Premium
The Fly
MapLight Therapeutics price target raised to $43 from $35 at Canaccord
3M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―